论坛讲座

论坛讲座

网站首页 > 论坛讲座 > 正文

新临床信息与医生处方:儿童用药说明书变化如何影响对儿童的处方?

发布时间: 2019/05/29 16:46:17     点击次数:次   打印本页

北航经商院 • 经济学双周论坛 第33期

尊敬的各位老师:

你们好!

“北航经商院 • 经济学双周论坛”将在本周五迎来第33期讨论,具体安排如下:  

时间:本周五(5月31日)中午12:00-14:00

地点:新主楼A618

在此诚挚邀请您参与讨论和分享!

题目:新临床信息与医生处方:儿童用药说明书变化如何影响对儿童的处方?

Title:New Clinical Information and Physician Prescribing: How Do Pediatric Labeling Changes Affect Prescribing to Children?

主讲人尹妮娜

Speaker:Nina YIN

摘要Abstract

本文研究了医生处方行为如何对药品说明书中更新的科学信息作出反应。我们关注了药品说明书中关于儿童用药效应的新信息。虽然人们相信这些信息可以改善对儿童的处方行为,但在过去却很少有相关的研究。我们的研究发现大多数的药品说明书变更都导致了对儿童处方的减少。而其中最显著的降低发生在当说明书表明药品对儿童无效时。这些结果表明说明书变更缓解了医生对于为儿童开具处方的不确定性也同时减少了不恰当的非说明书用药行为。

We explore how physician prescribing responds to new scientific information added to drug labels. We focus on label changes with new information about the effects of drugs in children. The information was expected to improve pediatric prescribing, but there is little evidence about the actual effects of these labeling changes. We find that most label changes lead to reductions in prescribing to children. The largest drop in prescribing occurs when the label indicates a drug is not effective for children. Results suggest that the labeling changes alleviated physician uncertainty about prescribing drugs to children and reduced some inappropriate off-label use.

主讲人简介(Introduction)

尹妮娜博士自2015年秋以来任职中央财经大学常任轨助理教授,她于2013-2015年间在美国杜兰大学做博士后。她于法国图卢兹大学获经济学博士, 尹妮娜博士的研究兴趣主要集中在产业经济学、健康经济学以及知识产权和创新经济学。她的研究发表于《美国健康经济学杂志》、《中国经济评论》和《牛津风险投资手册》。

Dr. Nina Yin is an tenure-track assistant professor at Central University of Finance and Economics, Beijing, China since September 2015. She was a postdoctoral research fellow at Tulane University (New Orleans, US) from 2013-2015. She received her Ph.D. in Economics from Toulouse School of Economics (Toulouse, France). Her research interests include industrial organization,health economics and the economics of innovation and intellectual property rights. Her articles has been published in American Journal of Health Economics, China Economic Review, and The Oxford Handbook of Venture Capital.